Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

(MedPage Today) -- SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline Depot) to everolimus (Afinitor...